The Histone Methyltransferase EZH2 Mediates Tumor Progression on the Chick Chorioallantoic Membrane Assay, a Novel Model of Head and Neck Squamous Cell Carcinoma  by Liu, Min et al.
The Histone Methyltransferase
EZH2 Mediates Tumor
Progression on the Chick
Chorioallantoic Membrane
Assay, a Novel Model of
Head and Neck Squamous
Cell Carcinoma1
Min Liu*,2, Christina Springstead Scanlon*,2,
Rajat Banerjee*, Nickole Russo*,
Ronald C. Inglehart*, Amanda L. Willis†,
Stephen J. Weiss† and Nisha J. D’Silva*,‡
*Periodontics and Oral Medicine, University of Michigan
School of Dentistry, Ann Arbor, MI; †Division of Molecular
Medicine and Genetics, Department of Internal Medicine,
Life Sciences Institute, University of Michigan, Ann Arbor,
MI; ‡Department of Pathology, University of Michigan
Medical School, Ann Arbor, MI
Abstract
Current in vivo models for head and neck squamous cell carcinoma (HNSCC) have limitations in simulating some
essential tumorigenic phenotypes, such as invasion. Most mouse models of human HNSCC are inadequate because
tumor cells are injected directly into the connective tissue, thereby bypassing the basement membrane of the surface
epithelium, the first barrier to invasion. In this manuscript, we establish the chick chorioallantoic membrane (CAM)
assay as an in vivomodel of human HNSCC tumor progression. Using the CAMmodel of HNSCC, we investigated the
role of enhancer of zeste homolog 2 (EZH2), a histone methyltransferase, in multiple aspects of HNSCC tumor pro-
gression. We found that knockdown of EZH2 reduced tumor size, angiogenesis, invasion, and metastasis of tumors
produced by grafting human HNSCC cells onto the CAM. In addition, we demonstrate that EZH2 expression mediates
amesenchymal phenotype in HNSCC cell lines andmouse tumors. These findings demonstrate the advantages of the
newly proposed CAMmodel of human HNSCC and highlight the emerging role of EZH2 in HSNCC tumor progression.
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Introduction
Head and neck squamous cell carcinoma (HNSCC) is the sixth most
common cancer globally [1]. The 5-year survival rate is about 50%,
which is poorer than breast cancer or melanoma [2]. New treatments
are required since current regimens have not improved survival in over
five decades. Understanding the mechanisms that control HNSCC
progression will provide new strategies for tumor eradication. Cur-
rent in vivo models for human HNSCC do not simulate invasion, an
essential tumorigenic phenotype, which may explain the weak correla-
tion between successful preclinical studies and clinical success with the
same antagonist.
The tumorigenic phenotypes or hallmarks of cancer include prolif-
eration, survival, invasion and metastasis, angiogenesis, and stemness
[3]. Cancer cell proliferation and survival promote tumor growth. In-
vasion is required for multiple steps in HNSCC progression includ-
ing initiation, local spread, and metastasis. During transformation of
a precancerous lesion to HNSCC, cells invade from the surface epithe-
lium, the tissue of origin of HNSCC, into the underlying connective
tissue. Invading cells destroy the basement membrane that separates
the epithelium from the connective tissue. Destruction of the basement
membrane and invasion are essential for development of HNSCC.
Thus, the basement membrane is the first, most robust structural
barrier to invasion [4]. Angiogenesis facilitates tumor growth and
spread, and stemness promotes tumor recurrence. Given the impor-
tance of these phenotypes in tumor progression, a robust cancer model
should recapitulate these phenotypes.
Many models have been developed in the last few decades to assess
the oncogenic phenotypes of HNSCC. However, most of these models
are in vitro systems that work with monolayer cultures, making these
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assays difficult to translate into clinical application. Recently, we devel-
oped an in vitro three-dimensional model for human HNSCC [5], but
this oral cancer equivalent model does not simulate the systemic im-
pact of invasion in vivo. Most mouse models of human HNSCC are
inadequate because tumor cells are injected directly into the connec-
tive tissue, thereby bypassing the basement membrane of the surface
epithelium, the first barrier to invasion. Given the importance of in-
vasion in tumor progression, we developed a novel in vivo model of
invasion of human HNSCC using the chicken embryo model.
The chicken embryo model has developed into the cornerstone of
cancer biology over many decades. This system has long served as
the principal model system for developmental biology and has provided
a pathway for critical conceptual development in genetics, immuno-
logy, virology, and cancer biology. The developing chicken egg attracted
interest from some of the earliest known scientific investigations dating
back to ancient Egypt and Greece [6]. The wide accessibility of chicken
eggs has helped to maintain the popularity of the model for thousands
of years. The chicken egg model has essentially contributed to the most
significant scientific discoveries of many Nobel laureates. For example,
the causal link between viruses and cancer [7], the first known oncogene
[8], the mechanism of reverse transcriptase and RNA viruses [9], and the
discovery of neural growth factor [10] are among the many key scientific
findings empowered by the chicken embryo system.
As early as 1913, scientists discovered that tumor grafts can be cul-
tivated by the rich capillary plexus of the chick chorioallantoic mem-
brane (CAM) surrounding the chicken embryo [11]. The CAMmodel
was developed as a model of angiogenesis in the 1970s [12], and by the
1980s, it was identified as a tool to study tumor metastasis [13]. These
early cancer studies using the chicken embryo system paved the way
for recently developed methods of studying invasion in cancer using
the CAM model.
Although the CAM assay has been known for many years, the bene-
fits of studying tumor invasion using this model are more recently rec-
ognized. The CAM is a highly vascularized membrane that is located
directly below the eggshell. This makes the CAM easy to access through
a small hole in the eggshell. The CAM is also made up primarily of type
IV collagen, which simulates the basement membrane of human oral
epithelium. The CAM assay has been used to measure invasion of
a variety of cell types, including fibroblasts [14] and several types of
cancer cells, including melanoma cells [15–17].
We propose that the chick embryo is an excellent model of invasion
and metastasis of human HNSCC. The CAM consists of the chorionic
epithelium separated from the underlying allantoic membrane by con-
nective tissue. The chorionic epithelium is separated from the connec-
tive tissue by an epithelial-derived basement membrane that contains
type IV collagen [14]. The cellular connective tissue contains type I
and III collagen and blood vessels. In this model, HNSCC cells are
seeded on top of the CAM and allowed to invade. Thus, the CAM
recapitulates intraoral human HNSCC progression including disrup-
tion of the basement membrane, complexity of the connective tissue,
angiogenesis, and metastasis. Even the histopathologic features simulate
invasion observed in HNSCC. Destruction of the basement membrane
can be easily visualized, and tumor growth, invasion into the connec-
tive tissue, and metastasis can be accurately quantified, making this a
valuable model for investigating progression of HNSCC.
In this study, we describe for the first time the use of the CAM to
investigate multiple tumorigenic phenotypes, including tumor growth,
invasion, metastasis, and angiogenesis in HNSCC. Recently, we showed
that enhancer of zeste homolog 2 (EZH2), a histone methyltransferase,
promotes progression of HNSCC by inducing multiple cancer pheno-
types, likely through methylation of multiple tumor suppressor gene
[18,19]. Using the CAM model, we investigated the role of EZH2
in tumor growth, angiogenesis, invasion, and metastasis in vivo. In
addition, we show the role of EZH2 in epithelial-mesenchymal transi-
tion (EMT) in mouse tumors, CAM tumors, and HNSCC cell lines.
Overall, we are able to establish the CAMmodel of HNSCC and inves-
tigate the role of EZH2 in several hallmarks of tumor progression.
Materials and Methods
Cell Culture
The HNSCC cell line, UM-SCC-29 (from Thomas Carey, Univer-
sity of Michigan) used in this study was validated by genotyping at the
University of Michigan DNA Sequencing Core and cultured as de-
scribed [20,21]. Cells were maintained in Dulbecco’s modified Eagle’s
medium (Gibco, Life Technologies, Grand Island, NY) supplemented
with 10% FBS and 1% penicillin/streptomycin. EZH2 in HNSCC
cells was stably downregulated as described [15]; scrambled shRNA
(shSCR) was used for control cells and shEZH2 for EZH2 knock-
down cells (Open Biosystems, Huntsville, AL). Cells were selected with
puromycin (Sigma-Aldrich Corp, St Louis, MO).
Immunoblot Analysis
Immunoblot analysis was performed as previously described [22].
NP-40 lysis buffer (1%) was used to lyse HNSCC cells. EZH2
(BDBiosciences, San Jose, CA) and glyceraldehyde 3-phosphate dehydro-
genase (GAPDH; Millipore, Billerica, MA) primary antibodies were
used. The secondary antibody used was HRP-conjugated anti-mouse
(Jackson ImmunoResearch Laboratories, West Grove, PA). SuperSignal
West Pico Chemiluminescent System (Thermo Scientific, Rockford, IL)
was use to visualize immunoreactive proteins, and ImageJ software was
used to quantify signal intensity (http://rsbweb.nih.gov/ij/).
Immunohistochemistry
Immunohistochemistry of tissue sections was performed as described
[21]. The primary antibodies used were vimentin (Proteintech, Chicago,
IL) and E-cadherin (BD Biosciences), and biotinylated goat anti-rabbit
and biotinylated goat anti-mouse secondary antibodies were used
(Biocare Medical, Concord, CA). Imaging of cells was performed at
the Microscopy and Image Analysis Core at the University of Michigan
on an Olympus BX-51 microscope. Representative fields were imaged
at ×20.
Murine Model of HNSCC Using Subcutaneous Injection
Athymic nude mice were used as described [23]. UM-SCC-29 cells
(1 × 106) were stably transduced with shSCR or shEZH2 and injected
subcutaneously to assess tumor growth [15]. Histopathologic analysis
of these tumors is shown in the present study.
Immunofluorescence Detection of Vimentin and E-Cadherin
Cells were labeled with vimentin (Proteintech) and E-cadherin (BD
Biosciences) primary antibodies diluted in 0.3% Triton X-100 over-
night at 4°C, washed, and incubated for 2 hours at room temperature
in an appropriate conjugated secondary antibody, washed, and incu-
bated in 4′,6-diamidino-2-phenylindole (DAPI; 1:3000) for 3 minutes.
Imaging of cells was performed at the Microscopy and Image Analysis
Core at the University of Michigan on an Olympus BX-51microscope.
Representative fields were imaged at ×100.
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Data Analysis
Statistical analysis was performed using Student’s t test with
GraphPad Prism (GraphPad Software, San Diego, CA). A P value
of <.05 was accepted as statistically significant.
Results
CAM In Vivo Model of HNSCC Tumor Progression
Figure 1 provides an overview perspective of the chicken embryo
and identifies where HNSCC tumors grow, invade, and metastasize
within the developing egg. HNSCC cells are seeded on the upper
CAM and destroy the basement membrane of the surface epithelium
to invade the connective tissue and blood vessels through which they
metastasize to the lower CAM and liver. Figure 2 provides an over-
view of the procedure and outlines the end-point assays including
tumor growth, invasion, angiogenesis, and metastasis. The University
of Michigan Unit for Laboratory Animal Medicine was consulted
regarding ethical use of the chicken embryo CAM for experiments.
Dropping the CAM. Fertilized commercial Lohmann White
Leghorn eggs were obtained from the Michigan State University
Department of Animal Sciences Poultry Farm. Before hatching, the
eggs were maintained at 24°C. Eggs were subsequently “hatched” in a
humidified incubator (Digital Sportsman Incubator; G.Q.F. Manufac-
turing, Savannah, GA) at 38°C with 60% humidity. The initial day
of incubation is considered day 0. On day 11, the following structures
were labeled on the egg using the ACE light source (Trevigen Inc,
Gaithersburg, MD): large blood vessel, umbilical cord, air sac, small
square window for the artificial air sac generation, and large window
area for seeding cancer cells. Using a Dremel 1100-N/25 7.2-Volt
Stylus Lithium-Ion Cordless Rota (Robert Bosch Tool Company,
Stuttgart, Germany), a 1-cm2 window was drilled on the top of the
eggshell, maintaining the outer eggshell membrane. A pinpoint hole
was prepared on the side of the egg at the location of the air sac. Hank’s
balanced salt solution (HBSS, 25 μl; Invitrogen, Life Technologies,
Grand Island, NY) was added on top of the 1-cm2 window at the top
of the egg. Then, using a 30.5-gauge needle, the outer eggshell mem-
brane was punctured at the location of the window so that the buffer
separated the outer eggshell membrane from the CAM. The small
pinpoint hole was vacuumed using a Pasteur pipette bulb, causing the
air bubble to move to the window and allowing the CAM to drop.
Then, the eggshell was drilled in the large window area, and blunt-ended
forceps were used to peel off the eggshell membrane without disturbing
the CAM. The large square hole was covered with parafilm and the
egg was place in the incubator without shaking.
Seeding HNSCC cells. HNSCC cells (1 × 106) were resuspended
in 5 μl of HBSS. The pipette was used to make a bead of cell and
medium that is dropped onto the CAM surface, without allowing the
pipette tip to touch the CAM. The square window on the egg was
sealed with Tegaderm HP Transparent Film Dressing. The eggs were
incubated without shaking for approximately 3 days.
Harvesting the CAM. Using a needle and syringe, a small amount
of 4% paraformaldehyde was injected onto the surface of the CAM.
Dissecting scissors were used to cut open the large window to visualize
Figure 1. Overview of the CAM model of tumor progression. Fluorescently labeled cancer cells are seeded on the upper CAM of the
chick embryo. The cancer cells invade the epithelium and basement membrane of the upper CAM and move through connective tissue
into the vasculature. Cancer cells can metastasize to the lower CAM or liver and lung of the developing chicken.
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the CAM and the tumor. Using scissors and a pair of forceps, each
CAM was lifted and cut around the tumor. The tumors and sur-
rounding CAM were transferred to a six-well dish containing 4% para-
formaldehyde and incubated at 4°C for 4 hours. The CAMs were
transferred to cold 30% sucrose and stored overnight at 4°C. The next
day, the CAMs were embedded in Optimal Cutting Temperature
Compound (Tissue-Tek, Sakura Finetek USA, Torrance, CA) and fro-
zen at −80°C until sectioning and staining. Tissue sections (8–10 μm)
were fixed in 4% paraformaldehyde for 5 minutes followed by staining
with hematoxylin and eosin.
End-point assays. For tumor growth and angiogenesis studies, sus-
pensions of 5 × 105 HNSCC cells with stable knockdown of EZH2
or controls were suspended in 5 μl of HBSS and plated on the upper
CAM. The window on the eggshell was resealed with adhesive tape
and eggs were returned to the incubator for 48 hours before harvest-
ing the tumor (n = 5 chick embryos per experimental group). Surface
area of the tumors was quantified using ImageJ software and statisti-
cally compared between control tumors and tumors with stable EZH2
knockdown. Angiogenesis was also quantified using red color density
within 200 μm of tumors in images using ImageJ software (http://
rsbweb.nih.gov/ij/) with the Colour Threshold plugin provided through
the University of Birmingham School of Dentistry web site (http://www.
dentistry.bham.ac.uk/landinig/software/software.html).
For invasion assays, cells were dyed with the lipophilic tracer, DiO
(a dialkylcarbocyanine derivative) before experiments. Tumor sections
were imaged at ×20, and invasive islands were quantified for each
image. Statistical analysis to compare the number of invasive islands
was performed.
For type IV collagen staining, the frozen tissue sections were fixed in
methanol, washed in phosphate-buffered saline (PBS), and blocked
with 0.1% BSA and 10% normal goat serum (NGS) in phosphate-
buffered saline for 30 to 60 minutes. The type IV collagen antibody
was diluted 1:1 in 0.1%BSA and 5%NGS and incubated on the tissue
Figure 2. Experimental procedure and time line of the CAM assay. Fertilized chicken eggs are hatched at day 0. On day 8, the developing
vasculature is identified and a window is opened on the egg to seed human cancer cells. On day 11, the egg can be reopened to harvest
the upper CAM containing the tumor to assess tumor growth, invasion, and angiogenesis. For metastasis studies, the egg is opened at
day 16 to collect the lower CAM and liver of the developing chicken. Quantitative PCR analysis of the collected tissues provides an
estimation of the number of human cancer cells that have invaded to the collected organs.
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sections for 2 hours. The coverslips were mounted with Prolong Gold
Antifade Reagent with DAPI (Invitrogen, Life Technologies).
For metastasis experiments, HNSCC cells were plated as described
for invasion studies at day 8. The lower CAM, liver, and lungs were
collected at day 16. Human DNA was quantified from DNA extracted
from the harvested tissues using Alu–polymerase chain reaction (PCR)
to compare metastasis from control and EZH2 knockdown tumors.
To generate the standard curve, genomic DNA from human HNSCC
cells (each human cell contains 6.6 pg of DNA) was mixed with 1 μg
of chicken genomic DNA in logarithmically increasing concentrations
as 0.1, 1.0, 10, 100, 1000, and 10000 cells. PCR was performed in
triplicate for each of the standards as well as the experimental samples.
The absolute number of metastatic human cells in the experimental
sample was calculated from the standard curve using linear regression.
EZH2 Enhances HNSCC Tumor Size on the CAM
Using the CAM in vivomodel, we investigated the impact of EZH2
on tumor growth in HNSCC. EZH2 is a master regulatory gene in
HNSCC that inhibits expression of tumor suppressor genes [18].
UM-SCC-29 cells with stable knockdown of EZH2 (UM-SCC-
29-shEZH2) and corresponding control cells with empty vector
(UM-SCC-29-shSCR) were seeded on the CAM (n = 5 for each
group). After 48 hours, the upper CAM was harvested from each chick
embryo and the surface area of the tumors was quantified (Figure 3A).
shRNA-mediated EZH2 knockdown was confirmed by immuno-
blot (Figure 3B). UM-SCC-29-shEZH2 cells produced tumors that
were significantly smaller than tumors generated by control cells (P =
.0460; Figure 3, A, dashed lines, and C ). Although the difference in
size between control and EZH2-deficient tumors is significant, the
variability in tumor size led to a higher P value than anticipated. A
larger sample size may have provided a lower P value to better reflect
the difference in tumor size between the groups. Additionally, because
some tumors appear to be more bulky than others, three-dimensional
analysis of tumor size may provide a more consistent estimation of
tumor size.
EZH2 Promotes Angiogenesis of HNSCC Tumors on the CAM
To investigate the impact of EZH2 on tumor-associated angio-
genesis, the area of blood vessels within 200 μm of the tumors were
quantified. shEZH2 tumors had decreased blood vessel area adjacent
to tumors compared to controls, indicating decreased angiogenesis of
the tumors (P = .0348; Figure 3, A, arrows, and D).
EZH2 Enhances Basement Membrane Disruption and
Invasion of HNSCC Tumors on the CAM
Tumors produced by UM-SCC-29-shSCR and UM-SCC-29-
shEZH2 were harvested and sectioned. Type IV collagen staining
was performed on the section to visualize disruption of the basement
Figure 3. EZH2promotes tumor growth and angiogenesis. Fluorescently labeledUM-SCC-29-SCRandUM-SCC-29-shEZH2cellswere seededon
the CAM. The upper CAM and tumors were collected 2 days later to analyze tumor growth and angiogenesis. White arrowheads show blood
vessel growthapproximating tumor (A, bright-field images).Dashed linesoutline tumorgenerated fromHNSCCcells onCAM[A, green fluorescent
protein (GFP) images]. Yellow arrowheads identify tumor islands migrating from primary tumor (A, GFP images). shRNA-mediated EZH2 knock-
downwasconfirmedby immunoblot (B). The average tumor growth andblood vessel densitywere calculated for both shSCRand shEZH2 tumors
(n= 5 for each group). Tumor size (C) and angiogenesis (D) were significantly decreased for shEZH2 tumors compared to control tumors.
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membrane on the upper CAM. Tumors produced with UM-SCC-29-
shSCR control cells showed more disruption of the basement mem-
brane than tumors with stable knockdown of EZH2 (Figure 4A). This
correlated with an increased number of invasive tumor islands in
UM-SCC-29-shSCR tumors than in tumors from cells with down-
regulation of EZH2 (P = .0053; Figure 4B).
EZH2 Promotes a Mesenchymal Phenotype of HNSCC
In Vitro and of Murine and CAM Tumors
Previously, we established that down-regulation of EZH2 inhibited
tumor growth in mice [18]. Control tumors that express high EZH2
exhibited an aggressive phenotype, and were comprised of cells with
large nuclei, little cytoplasm, and spindled morphology (arrows), that
invaded skeletal muscle (arrowheads; Figure 5A, upper panel). In con-
trast, tumors with EZH2 knockdown (Figure 5A, lower panel) exhib-
ited well-differentiated epithelial cells (keratin formation; arrowheads)
with increased cytoplasm (arrows), a less aggressive, more epithelioid
phenotype. To verify the impact of EZH2 on EMT, UM-SCC-29-
shEZH2 and UM-SCC-29-shSCR cells were plated at 60% confluence
and fixed. Immunofluorescence labeling of vimentin and E-cadherin
were performed, and five representative fields were imaged at ×100
(Figure 4B). Intensity of fluorescence was quantified and normalized
to the average intensity of shSCR cells. Control cells have a more mes-
enchymal phenotype with increased vimentin (P < .001) and decreased
E-cadherin (P = .0342) compared to cells with EZH2 knockdown
(Figure 5B). These findings are consistent with EZH2 inducing an
EMT phenotype. In addition, immunohistochemistry was performed
for vimentin and E-cadherin expression on CAM tumor sections from
shSCR and shEZH2-treated cells (Figure 5C ). Tumors with EZH2
knockdown had decreased vimentin expression (arrows) and higher
E-cadherin staining (arrows) than control tumors.
EZH2 Promotes Metastasis of HNSCC Tumor Cells on
the CAM
The invasive phenotype of tumor cells facilitates extension into the
surrounding structures and spread to distant sites (metastasis) through
the blood vessels. In the CAM model, metastasis requires invasion of
cells through the basement membrane of the surface epithelium and
into the blood vessels. Since EZH2 promotes invasion, we also in-
vestigated its effect on metastasis using the CAM model. UM-SCC-
29-shSCR and UM-SCC-29-shEZH2 cells were incubated on the
CAM of day 7 chick embryos. The eggs were incubated until day 15,
when the lower CAM and liver of the developing chick were har-
vested. The metastasized human cells in the chicken background were
quantified as described by quantitative PCR for amplification of
human Alu sequences [24,25], which eliminates cross-reactivity with
chicken DNA. When using control UM-SCC-29 cells, metastases
were detected in all lower CAM specimens and four of five livers of
the developing chicks. However, when using cells with reduced
EZH2 expression, no metastases were detected in either the lower
CAM or liver in any samples (Figure 5, D and E ; P = .0151).
Discussion
Over the past decade, the histone methyltransferase EZH2 has emerged
as a key player in tumor progression in many cancer types, including
HNSCC [18], breast [26,27], bronchial [28], lung [29], and prostate
[30]. Overexpression of EZH2 is often linked to poor prognosis and
advanced disease [31]. EZH2 expression is also correlated to increased
angiogenesis in tumors [32], in part due to paracrine signaling between
Figure 4. EZH2 promotes destruction of the basement membrane and invasion. Arrows (A) identify the basement membrane structure,
and tumor cells are labeled green. shSCR tumor cells are highly proliferative and invasive and destroy the basement membrane struc-
ture, but shEZH2 cells do not disrupt the basement membrane. Fewer invasive tumor islands (B) are observed on the histology of
shEZH2 tumors (sample 4 shown) than control tumors (sample 3 shown).
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tumor cells and associated vasculature [33]. EZH2 has also been
shown to have a role in cancer stem cell maintenance [34].
Our laboratory recently showed that EZH2 contributes to HNSCC
progression by hypermethylating the promoter region of the tumor
suppressor Rap1GAP [18,19]. We found that EZH2 is upregulated
in HNSCC cell lines compared to normal keratinocytes and that
EZH2 promotes tumor growth in vitro and in vivo in a mouse model
of HNSCC. In our previous study, we also evaluated the role of EZH2
in invasion using in vitro assays and found that EZH2 expression is
highly correlated with HNSCC cell invasion [18]. However, we were
unable to evaluate the impact of EZH2 on early invasive phenotypes,
i.e., destruction of the basement membrane of surface epithelium,
since, in the mouse model, tumor cells are injected directly into the
connective tissue. Invasion beyond the basement membrane is required
for transformation of a precancerous lesion (epithelial dysplasia) to
HNSCC [35].
In our current study, we chose the CAM in vivo model of tumor
progression to validate our previous in vitro findings about the role of
EZH2 in tumor invasion. In this study, which is, to our knowledge,
the first study to describe the use of the CAM model to investigate
tumor progression of HNSCC, we show that down-regulation of
EZH2 in HNSCC cells inhibits destruction of the basement mem-
brane and decreases invasion in vivo. In addition, we show that EZH2
mediates angiogenesis, growth, and metastasis of HNSCC.
There are many benefits of using the CAM to study tumor progres-
sion [36]. The CAM assay is completed in a short time period and is
Figure 5. EZH2 promotes EMT andmetastasis of HNSCC. (A) Histopathologic appearance of HNSCC tumors induced by UM-SCC-29-shSCR
and UM-SCC-29-shEZH2 cells inmice (A). Control tumors (upper panel) exhibit an aggressive andmesenchymal phenotypewith large nuclei,
little cytoplasm, and spindled morphology (arrows) and invasion into skeletal muscle (arrowheads). Knockdown of EZH2 (lower panel)
leads to more epithelioid, well-differentiated tumors containing cells with increased cytoplasm (arrows) and keratin formation (arrowheads).
To verify the impact of EZH2 on EMT, immunofluorescent labeling of vimentin and E-cadherin was performed and representative fields were
imaged at ×100 (B). Relative fluorescence was measured for five representative fields and quantified. Control cells have a more mesenchy-
mal phenotype with increased vimentin (P< .001) and decreased E-cadherin (P= .0342) compared to cells with EZH2 knockdown. HNSCC
cells were seeded on the CAM, and the lower CAM and liver were collected at day 15. Immunohistochemistry of EMT markers on CAM
sections shows decreased vimentin (arrows, C) and more intense E-cadherin expression of tumor cells (arrows, C) for shEZH2 tumors
compared to shSCR tumors. Metastases were observed for both the lower CAM and liver for controls, but no metastases were observed
for any shEZH2 tumors (D and E).
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relatively inexpensive compared to most in vivo models. The lack of
a mature immune system at the time the assay is performed allows
for use of different cell types and cells from different species. Because
the chicken embryo has been used scientifically for centuries, the
system is well described in the literature. Limitations of the assay in-
clude the extensive optimization and the large number of eggs that
are required to obtain consistent results. As in other in vivo systems,
tumors produced on the CAM exhibit some variability. Therefore,
it is appropriate to use a sample size of at least five eggs per group to
characterize differences.
In addition to establishing the CAM model of HNSCC tumor pro-
gression, we also evaluated the role of EZH2 expression on the histo-
pathologic presentation of HNSCC tumors and on the expression
of the EMT markers vimentin and E-cadherin. EMT is a process by
which nonmotile cells lose contact with neighboring cells and become
more motile [37]. EMT has been shown to promote HNSCC invasion,
metastasis, and tumor stemness [35]. While control cells produced
aggressive, mesenchymal-like tumors in vivo, tumors produced from
HNSCC cells with reduced EZH2 expression had a more epithelial-
like appearance, consistent with a less aggressive tumor. In addition,
knockdown of EZH2 leads to decreased vimentin and increased
E-cadherin expression in HNSCC cells and CAM tumors. These
findings indicate that EZH2 plays a role in mediating EMT in the
HNSCC cell line UM-SCC-29. We have previously shown that
EZH2-mediated invasion is not dependent on E-cadherin alteration
in the E-cadherin–deficient cell line, OSCC3. Therefore, other factors
that are still under investigation have a role in EZH2-mediated EMT,
independent of E-cadherin [19].
Our study investigating the role of EZH2 in tumor progression is
the first to describe the use of the CAM model to study progression
of HNSCC. The CAM model can be used to investigate tumor size,
angiogenesis, invasion, and metastasis of HNSCC. In addition, we
show that knockdown of EZH2 expression in HNSCC cells leads to
less aggressive tumors with a more epithelial-like phenotype. Together,
these studies highlight the emerging role of EZH2 in HNSCC pro-
gression. Future studies will elucidate the mechanistic role of EZH2
in EMT. In addition, the role of EZH2 inhibitors should be explored
as a therapeutic option for HNSCC treatment.
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